Ian McLeod

Comptroller/Controller/Auditor presso ANIKA THERAPEUTICS, INC.

Health Technology

Consumer Services

Profilo

Ian McLeod is currently the Chief Accounting Officer & Vice President at Anika Therapeutics, Inc. He previously worked as a Controller at ABIOMED, Inc. from 2007 to 2017 and as a Corporate Controller at Idenix Pharmaceuticals LLC from 2004 to 2007.
Mr. McLeod has an undergraduate degree from the University of Western Ontario and an MBA from McMaster University.

Posizioni attive di Ian McLeod

Società	Posizione	Inizio
ANIKA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	01/07/2021

Tutte le posizioni attive di Ian McLeod

Precedenti posizioni note di Ian McLeod

Società	Posizione	Fine
IDENIX PHARMACEUTICALS INC	Comptroller/Controller/Auditor	01/11/2007
ABIOMED, INC.	Comptroller/Controller/Auditor	-

Vedi nel dettaglio l'esperienza di Ian McLeod

Formazione di Ian McLeod

McMaster University	Masters Business Admin
University of Western Ontario	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ian McLeod

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ANIKA THERAPEUTICS, INC.	Health Technology

Aziende private	2
ABIOMED, Inc. ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.	Health Technology
Idenix Pharmaceuticals LLC Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.	Health Technology